LabConnect Executive and Leadership Team

Wesley Wheeler, the Chief Executive Officer at LabConnect, directs the company's overarching strategy and operational execution. Wheeler guides LabConnect's mission to provide global central laboratory and client-inspired support services for biopharmaceutical and CRO clients engaged in logistically and analytically complex studies. This leadership role involves ensuring the seamless integration of state-of-the-art technology with world-class laboratories to facilitate drug development from preclinical through Phase IV. Wheeler's focus remains on enhancing the company's ability to offer customized project and data management services, guaranteeing that high-quality samples are accurately connected to critical data. The Chief Executive Officer's strategic vision ensures LabConnect's preeminent position as a single provider for diverse central laboratory needs, driving efficiency and reliability across all client engagements. Wesley Wheeler champions the company's commitment to innovation and client satisfaction in the competitive landscape of clinical research support.

Mitchell Blumenfeld, the Chief Financial Officer at LabConnect, oversees all financial operations and strategic fiscal planning. Blumenfeld manages the company's financial health, ensuring robust resource allocation to support LabConnect's global central laboratory services and client-inspired support for complex clinical studies. This executive's responsibilities include financial forecasting, budget management, and driving profitability across all service lines, from routine testing to biorepository functions. Blumenfeld works closely with other C-suite leaders to align financial strategies with the company's mission of connecting high-quality samples to accurate data for biopharmaceutical and CRO clients. The Chief Financial Officer's expertise is critical in navigating the financial intricacies of drug development, supporting both routine and advanced analytical needs. Mitchell Blumenfeld's leadership ensures financial stability and enables strategic investments in state-of-the-art technology and world-class laboratories, reinforcing LabConnect's position as a preeminent provider in the market.

Michael Lalor, the Interim Chief Financial Officer & Vice President, Finance at LabConnect, provides critical financial oversight and strategic guidance during a transitional period. Lalor manages the financial health and operational efficiency of LabConnect's global central laboratory services, supporting complex studies for biopharmaceutical and CRO clients. This executive's responsibilities encompass financial planning, analysis, and ensuring the effective allocation of resources to maintain LabConnect's high standards in kit building, sample management, and data management. Lalor collaborates with the leadership team to uphold the company's mission of connecting high-quality samples to accurate data, reinforcing the value proposition of state-of-the-art technology and world-class laboratories. The Interim Chief Financial Officer & Vice President, Finance's role is vital in maintaining financial integrity and supporting the company's strategic objectives. Michael Lalor's leadership ensures continuity and financial stability, enabling LabConnect to continue serving as a preeminent provider for drug development needs.

Charles Castano, the Chief Technology Officer at LabConnect, architects and directs the company's technological infrastructure and innovation roadmap. Castano leads the integration of state-of-the-art technology across LabConnect's global central laboratory operations, ensuring the seamless delivery of services for logistically and analytically complex studies. This role involves overseeing the development and implementation of advanced data management systems, sample tracking solutions, and biorepository technologies that are crucial for biopharmaceutical and CRO clients. The Chief Technology Officer's strategic focus is on enhancing the company's unique combination of technology and world-class laboratories to provide customized project and data management services. Castano ensures that LabConnect's technological capabilities directly support the mission of connecting high-quality samples to accurate data, thereby accelerating drug development timelines. Charles Castano's leadership drives technological advancements that solidify LabConnect's standing as a preeminent provider for preclinical through Phase IV clinical development needs.